New antiviral treatments aim to eradicate hep C

PBS funding of new direct-acting antiviral (DAA) drugs could occur this year, but the real revolution in therapy will come with a move to interferon-free (IFN-free) regimens, according to Professor Greg Dore, head of the viral hepatitis clinical research program at the Kirby Institute, Sydney.

Phase III studies of IFN-free therapy will commence this year, heralding an era of treatment with reduced toxicity, simplified dosing and monitoring, he wrote in the Medical Journal of Australia.

“If we are going to scale up hepatitis C treatment with new